The biotech company's shares surged after announcing an ambitious plan for its sublingual drug delivery technology and boosting its 2026 financial outlook.
The non-dilutive capital is aimed at advancing the company's battery manufacturing capabilities and bolstering its position in the U.S. supply chain.
The approval covers a first-line maintenance treatment for an aggressive form of small cell lung cancer, a historically difficult-to-treat disease.
The ongoing government shutdown has postponed the release of key economic data, leaving the Federal Reserve and investors in the dark.
Autonomous trucking firm's shares rose 2.2% in after-hours trading after the billionaire's fund disclosed a 5.7% passive investment.
The regulator's green light for Rhapsido, a first-in-class oral treatment for chronic hives, positions the company to challenge injectable rivals.
A multibillion-dollar AI agreement is in limbo as the US Commerce Department scrutinizes the UAE's ties to Beijing, potentially impacting Nvidia's growth.
Gene therapy candidate TSHA-102 for Rett syndrome receives key designation, paving the way for an accelerated regulatory pathway.